Technology
Biology Technology
| 2/9/2010 | NEW YORK , Feb. 9 Reportlinker.com announces that a new market research report is available in its catalogue: The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) http://www.reportlinker.com/p0176223/The-Clinical-Laboratory-Services-Market-Growth-Opportunities-Competitive... [Comments] |
Reportlinker Adds SNP Genotyping and Analysis Markets
| 2/9/2010 | NEW YORK , Feb. 9 Reportlinker.com announces that a new market research report is available in its catalogue: SNP Genotyping and Analysis Markets http://www.reportlinker.com/p0176225/SNP-Genotyping-and-Analysis-Markets.html Because SNPs (single nucleotide polymorphisms),are the most common type of genetic variation betw... [Comments] |
endpoint Saves Money and Time for Medical Research Teams Through PULSE
| 2/9/2010 | SAN FRANCISCO , Feb. 9 endpoint Clinical ( www.endpointclinical.com ), a leader in Integrated Voice Response (IVR)/Integrated Web Response (IWR) systems, announced today that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of c... [Comments] |
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
| 2/9/2010 | SAN DIEGO , Feb. 9 Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that Felix J. Baker , Ph.D., has been appointed to the Company's Board of Directors. Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest shareholder. "Ardea's impr... [Comments] |
| 2/9/2010 | CHENGDU, China , Feb. 9 /PRNewswire-Asia-FirstCall/ -- TianyinPharmaceutical Co., Inc., (NYSE Amex: TPI ), a manufacturer and supplier ofmodernized traditional Chinese medicine ("TCM") and Western Pharmaceuticalsbased in Chengdu, China , today announced that it expects operational benefitsfrom the recently published Guide to Reform of Pricing Mechanism... [Comments] |
Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
| 2/9/2010 | PEORIA, Ariz. , Feb. 9 A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States . Although not life threatening,... [Comments] |
New Funding Validates Importance of Divergence's Work on Nematodes
| 2/9/2010 | Divergence receives grant funding of $500,000 to prevent crop damage by nematodes as the Divergence and National Corn Growers Association continues collaboration. (PRWEB) February 9, 2010 -- Divergence, Inc. announced today that the company has recently received two Small Business Innovation Research (SBIR) grants totaling $500,000, along with... [Comments] |
| 2/9/2010 | SILVER SPRING, Md. , Feb. 9 United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will release its fourth quarter and annual 2009 financial results before market open on Tuesday, February 16, 2010 . United Therapeutics will host a half-hour teleconference on Tuesday, February 16, 2010 , at 9:00 a.m. Eastern Time . ... [Comments] |
| 2/9/2010 | HUNTINGTON BEACH, California and AMSTERDAM , February 9 Agendia, a world leader in molecular cancer diagnostics, announced today thatit has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receivecommercial samples of MammaPrint, its FDA-cleared breast cancer recur... [Comments] |
CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting
| 2/9/2010 | CARMEL, Ind. , Feb. 9 The American Psychiatric Association (APA) has chosen CME Enterprise as the sole medical education partner to prepare and manage all industry-supported symposia (ISS) programming at its annual meeting in New Orleans, Louisiana , from May 22-26, 2010 . CME Enterprise will manage all elements of industry-supported symposia progr... [Comments] |
Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
| 2/9/2010 | NEW YORK , Feb. 9 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.(NYSE Amex: NBS ) ("NeoStem" or the "Company"), an internationalbiopharmaceutical company with operations in the U.S. and China , announcedtoday that its stem cell collection network has expanded into the southwesternregion of the U.S. with the addition of the physician group at... [Comments] |
Medicine Technology
SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage
| 2/9/2010 | PHOENIX , Feb. 9 More than 6,300 Maricopa County residents selected SCAN Health Plan Arizona as their Medicare Advantage Plan (MAPD) for 2010, far exceeding SCAN's enrollment projections. Eligible individuals may continue to join SCAN until March 31, 2010 . SCAN Health Plan Arizona, which began offering MAPD coverage in 2009, is affiliated w... [Comments] |
STD Med Inc. Acquires Facility for Manufacturing and Start-Ups
| 2/9/2010 | STOUGHTON, Mass. , Feb. 9 STD Med, Inc., a manufacturer and innovator of medical devices located in Stoughton, Massachusetts is pleased to announce the acquisition of a new 32,000 sq. ft. facility in West Bridgewater, Massachusetts . This is in addition to the current footprint of 120,000 sq. ft. "We are excited to be growing and advancing the company du... [Comments] |
SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly
| 2/9/2010 | NEW YORK , Feb. 9 LIVESTRONG Quarterly is a new online, print and print-on-demand publication from LIVE STRONG . The magazine features profiles of survivors and supporters in the fight against cancer; resources and information about cancer prevention and treatment; and general articles about health, fitness and wellness. "As a thr... [Comments] |
Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
| 2/9/2010 | NEW YORK , Feb. 9 Reportlinker.com announces that a new market research report is available in its catalogue: Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 http://www.reportlinker.com/p0176366/Atrial-Fibrillation---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html Atrial Fibrillation -... [Comments] |
Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
| 2/9/2010 | CAMBRIDGE, Mass. , Feb. 9 Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical t... [Comments] |
Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
| 2/9/2010 | SAN DIEGO , Feb. 9 Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market t... [Comments] |
| 2/9/2010 | SAN DIEGO , Feb. 9 Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedi... [Comments] |
| 2/9/2010 | FRANKLIN, Mass. , Feb. 9 Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney , M.D., the C... [Comments] |
FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging
| 2/9/2010 | Initiative to focus on 3 types of procedures with high radiation doses SILVER SPRING, Md. , Feb. 9 The U.S. Food and Drug Administration today announced an initiative to reduce unnecessary radiation exposure from three types of medical imaging procedures: computed tomography (CT), nuclear medicine studies, and fluoroscopy. These... [Comments] |
Gerresheimer Achieves Sales Target for 2009
| 2/9/2010 | DUSSELDORF, Germany, February 9 - Profit Margin Better Than Expected - Sales on like-for-like basis almost at prior year level (-1.5 percent) - Adjusted EBITDA margin of 19.2 percent (on like-for-like basis) better than expected - CEO Dr. Axel Herberg: "We have demonstrated our stability and profitability in a d... [Comments] |
| 2/9/2010 | BANNOCKBURN, Ill. , Feb. 9 Glycemion Strategies, Inc., an Illinois -based company that develops strategic initiatives for diabetic consumers and their professional healthcare providers, announced today a new Emergency Medical Data Retrieval Program to benefit the 30,000 US Diabetes Educators and the more than 4 million diabetic clients they serve.... [Comments] |
(Date:2/8/2010)... Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences ... operational and financial results for the second quarter ... . ,, "After rigorous evaluation of numerous global ... a clinical-stage, Melbourne -based drug development company, ... David Allan , Chairman & CEO of YM ...
(Date:2/8/2010)... Feb. 8 Corgenix Medical Corporation (OTC ... diagnostic test kits, and Tulane University , today ... combat viral hemorrhagic fever (VHF), an effort that will ... for Corgenix over the life of the contract. ... a five-year contract totaling $15,224,927 to ...
(Date:2/8/2010)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Ph.D. to its Board of Directors effective immediately. He ... Receptos, Inc., and former Executive Chairman of Biogen Idec, ... Bill Rastetter to our Board of Directors," said ... Board of Neurocrine Biosciences. "The company is very fortunate ...
(Date:2/5/2010)... test to find undetected landmines. , Students from the ... glows green when it comes into contact with chemicals ... mixed into a colourless solution that, when sprayed on ... presence of landmines. , Researchers say that the ... from the air onto areas thought to contain landmines, ...
Breaking Biology Technology:YM BioSciences reports second quarter 2010 operational and financial results 2YM BioSciences reports second quarter 2010 operational and financial results 3YM BioSciences reports second quarter 2010 operational and financial results 4YM BioSciences reports second quarter 2010 operational and financial results 5YM BioSciences reports second quarter 2010 operational and financial results 6YM BioSciences reports second quarter 2010 operational and financial results 7YM BioSciences reports second quarter 2010 operational and financial results 8YM BioSciences reports second quarter 2010 operational and financial results 9YM BioSciences reports second quarter 2010 operational and financial results 10YM BioSciences reports second quarter 2010 operational and financial results 11YM BioSciences reports second quarter 2010 operational and financial results 12Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors 2[0] YM BioSciences reports second quarter 2010 operational and financial results[0] Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents[0] Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors[0] Simple test could offer cheap solution to detecting landmines
... Care managers can now quickly and easily access ... environment of care (EC) compliance with the ... interviews with EC experts called "EC Bits."EC Bits audio ... feature expert advice to help keep EC managers ...
... CITY, Calif., Feb. 24 Pearl Therapeutics announced,today that ... Oxford,Finance Corporation and Silicon Valley Bank, a member ... provided the capital which will be drawn in two,tranches. ... to be working with Oxford and SVB. They ...
... Feb. 24 Novasys Medical, Inc., a ... today that Noridian,Administrative Services, LLC, a regional ... now covering the non-surgical Renessa treatment,for women ... currently,administers benefits for approximately 4 million Medicare ...
Other Biology Technology:Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues 2Pearl Therapeutics Secures $8 Million in Debt Financing 2Pearl Therapeutics Secures $8 Million in Debt Financing 3Noridian Medicare Now Covers Renessa(R) Treatment for Incontinence in Women 2(Date:2/9/2010)... February 9 Debiopharm ... companies with,a focus on the development of ... announced the signature of an exclusive licence ... commercialisation of Debio 025,(alisporivir), a selective, first-in-class ... virus (HCV) effect. The product is currently ...
(Date:2/8/2010)... , Feb. 8 Cost reductions ... Products (Nasdaq: AHPI ) narrowly back into profitability ... Sales for the quarter ended December 31, 2009 ... million during the same quarter last year to ... Allied,s costs of sales were reduced even more sharply, ...
(Date:2/8/2010)... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... for the fourth quarter and year-end 2009 following the ... 2010 . ,, Paul Hamelin , President ... Officer, will host an investment community conference call beginning ... February 26, 2010 to discuss these results and ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Impact Factor names Cell top research journal 8967 1Rotary Marks Progress in Drive to Eradicate Polio 49766 1Rotary Marks Progress in Drive to Eradicate Polio 49766 2Rotary Marks Progress in Drive to Eradicate Polio 49766 3ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 1ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 2[0] Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025[0] Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions[0] Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
... Therapeutics Limited,one of the UK,s leading pre-IPO biotechnology ... study with its oral, once-daily experimental,cancer therapy CHR-2797 ... (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM),who ... chemotherapy., Headline data from the study, which ...
... CARLOS, Calif., Dec. 12 Nuvelo, Inc.,(Nasdaq: ... patient in a Phase 2,proof-of-concept trial of alfimeprase ... has also been granted fast track designation by ... in this indication. Fast,track designation, which was mandated ...
Other Medicine Technology:Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 3Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |